Based on the recent IRIS-A trial presented at ASCO 2026, would adjuvant capecitabine plus trastuzumab be a reasonable consideration for a premenopausal patient with a unifocal, microinvasive (0.7 mm), ER/PR-positive, HER2-positive invasive ductal carcinoma (pT1miN0)?

Based on prior retrospective experience that compared outcomes of patients with small, node-negative HER2-positive breast cancer based on whether or not such patients received adjuvant systemic anti-HER2 +/- chemotherapy (summarized by our group in a review article - Johnson et al., PMID 35389302), ...